Does the media prefer PRAX or ZLAB?

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Zai Lab. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 2 mentions for Zai Lab. Praxis Precision Medicines' average media sentiment score of 1.45 beat Zai Lab's score of 0.72 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or ZLAB?

In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than Zai Lab. MarketBeat recorded 9 mentions for Crinetics Pharmaceuticals and 2 mentions for Zai Lab. Crinetics Pharmaceuticals' average media sentiment score of 0.94 beat Zai Lab's score of 0.72 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZLAB or TGTX?

TG Therapeutics has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.75 -$175.54M -$1.62 N/A TG Therapeutics $616.29M 13.92 $447.18M $2.86 19.59

Is ZLAB or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Zai Lab's net margin of -39.29%. TG Therapeutics' return on equity of 88.73% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer ZLAB or TGTX?

In the previous week, TG Therapeutics had 3 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for TG Therapeutics and 2 mentions for Zai Lab. TG Therapeutics' average media sentiment score of 1.33 beat Zai Lab's score of 0.72 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IBRX or ZLAB?

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 65.64 -$351.40M -$0.85 N/A Zai Lab $460.16M 4.75 -$175.54M -$1.62 N/A

Is IBRX or ZLAB more profitable?

Zai Lab has a net margin of -39.29% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Zai Lab -39.29% -24.32% -15.52%

Does the media prefer IBRX or ZLAB?

In the previous week, ImmunityBio had 3 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for ImmunityBio and 2 mentions for Zai Lab. ImmunityBio's average media sentiment score of 1.67 beat Zai Lab's score of 0.72 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SYRE or ZLAB?

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 2 articles in the media. Spyre Therapeutics' average media sentiment score of 1.83 beat Zai Lab's score of 0.72 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Zai Lab (ZLAB) Competitors

$19.22 -0.46 (-2.34%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$19.24 +0.02 (+0.08%)

As of 07/24/2026 07:34 PM Eastern

Compare

ZLAB vs. PRAX, CRNX, TGTX, IBRX, and SYRE

Should you buy Zai Lab stock or one of its competitors? MarketBeat compares Zai Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zai Lab include Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Zai Lab compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Praxis Precision Medicines currently has a consensus target price of $563.50, suggesting a potential upside of 73.22%. Zai Lab has a consensus target price of $40.00, suggesting a potential upside of 108.12%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Zai Lab. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 2 mentions for Zai Lab. Praxis Precision Medicines' average media sentiment score of 1.45 beat Zai Lab's score of 0.72 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,060.74	-$303.27M	-$13.37	N/A
Zai Lab	$460.16M	4.75	-$175.54M	-$1.62	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Zai Lab	-39.29%	-24.32%	-15.52%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Summary

Praxis Precision Medicines beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than Zai Lab. MarketBeat recorded 9 mentions for Crinetics Pharmaceuticals and 2 mentions for Zai Lab. Crinetics Pharmaceuticals' average media sentiment score of 0.94 beat Zai Lab's score of 0.72 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a net margin of -39.29% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Zai Lab's return on equity of -24.32% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Zai Lab	-39.29%	-24.32%	-15.52%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zai Lab has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,146.56	-$465.32M	-$5.13	N/A
Zai Lab	$460.16M	4.75	-$175.54M	-$1.62	N/A

Crinetics Pharmaceuticals has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Crinetics Pharmaceuticals presently has a consensus price target of $78.27, suggesting a potential downside of 6.52%. Zai Lab has a consensus price target of $40.00, suggesting a potential upside of 108.12%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Zai Lab beats Crinetics Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Zai Lab compare to TG Therapeutics?

Zai Lab (NASDAQ:ZLAB) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

TG Therapeutics has a net margin of 65.95% compared to Zai Lab's net margin of -39.29%. TG Therapeutics' return on equity of 88.73% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
TG Therapeutics	65.95%	88.73%	43.44%

Zai Lab presently has a consensus target price of $40.00, suggesting a potential upside of 108.12%. TG Therapeutics has a consensus target price of $53.33, suggesting a potential downside of 4.83%. Given Zai Lab's stronger consensus rating and higher probable upside, equities analysts clearly believe Zai Lab is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

TG Therapeutics has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.75	-$175.54M	-$1.62	N/A
TG Therapeutics	$616.29M	13.92	$447.18M	$2.86	19.59

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zai Lab has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

In the previous week, TG Therapeutics had 3 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for TG Therapeutics and 2 mentions for Zai Lab. TG Therapeutics' average media sentiment score of 1.33 beat Zai Lab's score of 0.72 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Zai Lab on 13 of the 15 factors compared between the two stocks.

How does Zai Lab compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 100.00%. Zai Lab has a consensus target price of $40.00, suggesting a potential upside of 108.12%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, ImmunityBio had 3 more articles in the media than Zai Lab. MarketBeat recorded 5 mentions for ImmunityBio and 2 mentions for Zai Lab. ImmunityBio's average media sentiment score of 1.67 beat Zai Lab's score of 0.72 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Zai Lab has a net margin of -39.29% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Zai Lab	-39.29%	-24.32%	-15.52%

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	65.64	-$351.40M	-$0.85	N/A
Zai Lab	$460.16M	4.75	-$175.54M	-$1.62	N/A

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ImmunityBio and Zai Lab tied by winning 8 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 2 articles in the media. Spyre Therapeutics' average media sentiment score of 1.83 beat Zai Lab's score of 0.72 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has higher earnings, but lower revenue than Zai Lab. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,091.36	-$155.20M	-$2.08	N/A
Zai Lab	$460.16M	4.75	-$175.54M	-$1.62	N/A

Spyre Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Zai Lab	-39.29%	-24.32%	-15.52%

Spyre Therapeutics currently has a consensus target price of $101.42, suggesting a potential downside of 0.70%. Zai Lab has a consensus target price of $40.00, suggesting a potential upside of 108.12%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Spyre Therapeutics beats Zai Lab on 9 of the 15 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.19B	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-11.86	21.48	27.14	23.64
Price / Sales	4.75	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.01	7.88	10.28	6.07
Net Income	-$175.54M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.85%	-3.82%	-1.27%	-0.63%
1 Month Performance	3.78%	-2.61%	-0.37%	-2.00%
1 Year Performance	-48.29%	32.79%	18.30%	13.62%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.9311 of 5 stars	$19.22 -2.3%	$40.00 +108.1%	-49.1%	$2.19B	$460.16M	N/A	1,784
PRAX Praxis Precision Medicines	4.1087 of 5 stars	$314.56 -3.2%	$563.50 +79.1%	+460.8%	$9.06B	$8.55M	N/A	110	Positive News
CRNX Crinetics Pharmaceuticals	2.238 of 5 stars	$83.67 +0.1%	$78.27 -6.5%	+175.3%	$8.81B	$7.70M	N/A	210	Short Interest Decrease
TGTX TG Therapeutics	2.5565 of 5 stars	$55.01 -3.7%	$53.33 -3.0%	+53.4%	$8.74B	$616.29M	19.23	290	Positive News
IBRX ImmunityBio	2.8227 of 5 stars	$7.79 -5.2%	$14.20 +82.3%	+135.9%	$8.61B	$113.29M	N/A	590	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors

ZLAB vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Zai Lab compare to Praxis Precision Medicines?

Summary

How does Zai Lab compare to Crinetics Pharmaceuticals?

Summary

How does Zai Lab compare to TG Therapeutics?

Summary

How does Zai Lab compare to ImmunityBio?

Summary

How does Zai Lab compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zai Lab (ZLAB) Competitors

ZLAB vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Zai Lab compare to Praxis Precision Medicines?

Do analysts prefer PRAX or ZLAB?

Does the media prefer PRAX or ZLAB?

Which has preferable earnings and valuation, PRAX or ZLAB?

Is PRAX or ZLAB more profitable?

Do insiders and institutionals hold more shares of PRAX or ZLAB?

Which has more volatility and risk, PRAX or ZLAB?

Summary

How does Zai Lab compare to Crinetics Pharmaceuticals?

Does the media prefer CRNX or ZLAB?

Is CRNX or ZLAB more profitable?

Do insiders & institutionals hold more shares of CRNX or ZLAB?

Which has stronger earnings & valuation, CRNX or ZLAB?

Which has more risk & volatility, CRNX or ZLAB?

Do analysts prefer CRNX or ZLAB?

Summary

How does Zai Lab compare to TG Therapeutics?

Is ZLAB or TGTX more profitable?

Do analysts recommend ZLAB or TGTX?

Which has better earnings and valuation, ZLAB or TGTX?

Do institutionals and insiders have more ownership in ZLAB or TGTX?

Which has more risk & volatility, ZLAB or TGTX?

Does the media prefer ZLAB or TGTX?

Summary

How does Zai Lab compare to ImmunityBio?

Do analysts recommend IBRX or ZLAB?

Does the media prefer IBRX or ZLAB?

Which has more volatility & risk, IBRX or ZLAB?

Is IBRX or ZLAB more profitable?

Which has higher valuation and earnings, IBRX or ZLAB?

Do institutionals & insiders have more ownership in IBRX or ZLAB?

Summary

How does Zai Lab compare to Spyre Therapeutics?

Do insiders & institutionals hold more shares of SYRE or ZLAB?

Does the media favor SYRE or ZLAB?

Which has stronger valuation and earnings, SYRE or ZLAB?

Which has more risk & volatility, SYRE or ZLAB?

Is SYRE or ZLAB more profitable?

Do analysts prefer SYRE or ZLAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools